1
|
β-Nitrostyrene derivatives as broad range potential antifungal agents targeting fungal cell wall. Eur J Med Chem 2022; 240:114609. [DOI: 10.1016/j.ejmech.2022.114609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 06/26/2022] [Accepted: 07/10/2022] [Indexed: 11/22/2022]
|
2
|
Denardi LB, Oliveira V, de Jesus FPK, Dalla-Lana BH, Santurio JM, Zanette RA, Alves SH. In vitro interactions of azoles and echinocandins against clinical strains of Aspergillus flavus. Med Mycol 2019; 56:1006-1011. [PMID: 29294129 DOI: 10.1093/mmy/myx159] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2017] [Accepted: 12/06/2017] [Indexed: 02/06/2023] Open
Abstract
Combinations of an azole (itraconazole, voriconazole, or posaconazole) with an echinocandin (caspofungin, micafungin, or anidulafungin) were tested against 20 clinical isolates of Aspergillus flavus according to EUCAST guidelines. The interactions were determined using two endpoints-minimal effective concentration (MEC) and minimal inhibitory concentration (MIC)-via calculation of the fractional inhibitory concentration (FIC) index. A higher prevalence of synergistic interactions was observed for MIC, whereas indifference was the most frequent outcome according to MEC among the 20 strains. Combined treatment of A. flavus with these two important classes of antifungals should be explored further in in vivo studies.
Collapse
Affiliation(s)
- Laura Bedin Denardi
- Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil.,Laboratório de Pesquisas Micológicas, Departamento de Microbiologia e Parasitologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil
| | - Vanessa Oliveira
- Laboratório de Pesquisas Micológicas, Departamento de Microbiologia e Parasitologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil
| | - Francielli Pantella Kunz de Jesus
- Laboratório de Pesquisas Micológicas, Departamento de Microbiologia e Parasitologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil.,Programa de Pós-Graduação em Farmacologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil
| | - Bianca Hoch Dalla-Lana
- Laboratório de Pesquisas Micológicas, Departamento de Microbiologia e Parasitologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil
| | - Janio Morais Santurio
- Laboratório de Pesquisas Micológicas, Departamento de Microbiologia e Parasitologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil.,Programa de Pós-Graduação em Farmacologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil
| | - Régis Adriel Zanette
- Programa de Pós Graduação em Ciências Biológicas: Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
| | - Sydney Hartz Alves
- Programa de Pós-Graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil.,Laboratório de Pesquisas Micológicas, Departamento de Microbiologia e Parasitologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil
| |
Collapse
|
3
|
Candoni A, Aversa F, Busca A, Cesaro S, Girmenia C, Luppi M, Rossi G, Venditti A, Nosari AM, Pagano L. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. J Chemother 2014; 27:1-12. [DOI: 10.1179/1973947814y.0000000224] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
4
|
Invasive pulmonary aspergillosis in critically ill immunocompetent patients. MEDECINE INTENSIVE REANIMATION 2013. [DOI: 10.1007/s13546-013-0686-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Fallon RM, Girotto JE. A review of clinical experience with newer antifungals in children. J Pediatr Pharmacol Ther 2012; 13:124-40. [PMID: 23055874 DOI: 10.5863/1551-6776-13.3.124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Fungal infections are a significant cause of morbidity and mortality in immunocompromised children. Since the beginning of the 21st century, many new antifungals including the echinocandins (i.e., caspofungin, micafungin, anidulafungin) and the newer generation triazoles (i.e., voriconazole and posaconazole) have received Food and Drug Administration approval. Unfortunately, despite making great strides in the adult arena, these agents are not currently approved in the pediatric population. However, pharmacokinetic data and clinical experiences with these agents in infants, children, and adolescents are mounting. As such, this review will discuss key concepts in pediatric pharmacology and clinical use of these newer antifungal agents.
Collapse
Affiliation(s)
- Renee M Fallon
- Maine Medical Center, Department of Pharmacy Services, Portland, Maine
| | | |
Collapse
|
6
|
Calvo E, Pastor FJ, Salas V, Mayayo E, Guarro J. Combined Therapy of Voriconazole and Anidulafungin in Murine Infections by Aspergillus flavus. Mycopathologia 2011; 173:251-7. [DOI: 10.1007/s11046-011-9507-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Accepted: 10/30/2011] [Indexed: 10/14/2022]
|
7
|
Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Mycoses 2011; 54:234-42. [PMID: 19906090 DOI: 10.1111/j.1439-0507.2009.01808.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Combination treatment of paediatric invasive fungal infections (IFIs) has rarely been reported. A total of 17 children with 19 IFI episodes were enrolled in the study. The median age of the patients was 5.3 (range 0.5-17) years. IFI was classified as proven in 4, probable in 12 and possible in 3 episodes. These patients received empiric antifungal treatment, which consisted of liposomal amphotericin B (LAmB) monotherapy for a median duration of 12 days (range 3-69 days). All patients were refractory to LAmB; therefore, caspofungin was added to the therapy in 11 patients. In the remaining six patients, LAmB was ceased and a combination of caspofungin and voriconazole was started. Among the patients who received caspofungin + LAmB, four did not show favourable response and the combination was switched to caspofungin + voriconazole. The median (range) and total duration of the therapy were 7 (3-14) days and 91 patient days for LAmB + caspofungin combination and 49 (7-126) days and 516 patient days for caspofungin + voriconazole combination. We found a favourable response rate of 68.4% in 16 proven or probable IFI episodes. Twelve-week survival rate of these patients was 75%. No serious side effect was observed among the patients. Our data suggest that combination antifungal therapy is safe and effective in children with haematological malignancies.
Collapse
Affiliation(s)
- Deniz Yilmaz
- Pediatric Hematology Department, Ege University School of Medicine, Izmir, Turkey.
| | | | | | | | | | | |
Collapse
|
8
|
des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, François N, Corm S, Lemaitre L, Poulain D, Yakoub-Agha I, Alfandari S, Sendid B. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther 2011; 36:152-60. [DOI: 10.1111/j.1365-2710.2010.01166.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Berthe A, Duclos A, Ray-coquard I, Colin C, Bleyzac N. [Assessment of adherence to Afssaps guidelines for the prescription of antifungals in pediatric hemato-oncology]. Med Mal Infect 2010; 41:25-32. [PMID: 21087832 DOI: 10.1016/j.medmal.2010.09.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2010] [Revised: 06/30/2010] [Accepted: 09/30/2010] [Indexed: 11/29/2022]
Abstract
OBJECTIVE This study had for aim to identify factors limiting the implementation of clinical guidelines related to the use of expensive antifungal drugs in pediatric hemato-oncology. DESIGN A retrospective study was conducted in a Lyon teaching hospital (France), from February to December 2008. The compliance of antifungal prescription to French guidelines was assessed. Audit findings were interpreted using both semi-directed interviews of six prescribers (qualitative approach) and statistical analysis of prescriptions (quantitative approach). RESULTS Fifty antifungal prescriptions were studied. The compliance with clinical guidelines reached 66% (CI 95% 52-80%). The semi-directed interviews revealed that five issues may have influenced the adherence of prescribers with recommended practices: the guidelines, the molecule, the prescriber, the child, and practice settings. The statistical analysis did not reveal any link between the prescriber's activities or his department and the compliance with guidelines. A significant association was found between the documentation of infection and the non-conformity of antifungal prescriptions (p=0.02). CONCLUSIONS This study, combining qualitative and quantitative assessments, addressed potential issues related to the implementation of guidelines in specific patient groups or to their adaptation in the context of pediatric hematology-oncology. Harmonization of practices related to the widespread use of antifungal associations is required.
Collapse
Affiliation(s)
- A Berthe
- UMR 5558, service de pharmacie, institut d'hémato-oncologie pédiatrique, 1 place Joseph-Renault, Lyon, France
| | | | | | | | | |
Collapse
|
10
|
Bonatti H, Lass-Floerl C, Angerer K, Singh N, Lechner M, Stelzmueller I, Singh R, Schmid T, Geltner C. Successful management of postpneumonectomy Aspergillus pleural empyema by combined surgical and anti-fungal treatment with voriconazole and caspofungin. Mycoses 2009; 53:448-54. [PMID: 19496935 DOI: 10.1111/j.1439-0507.2009.01729.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Aspergillus pleural empyema is a rare but often fatal infection complicating thoracic surgery. Three men and one woman aged 23-47 years were diagnosed with Aspergillus pleural empyema after lung resection. Underlying diseases were lung cancer (n = 2), Hodgkin's disease (n = 1) and thoracic trauma (n = 1). The treatment protocol consisted of systemic anti-fungal treatment with caspofungin and voriconazole, intrapleural application of amphotericin B and surgical debridement with secondary closure of the leaking bronchial stump. Two patients with chronic Aspergillus pleural empyema had been pretreated with itraconazole and/or amphotericin B. Two patients were treated with a thoracostoma. Two patients had undergone pneumonectomy for previously diagnosed pulmonary aspergillosis. Caspofungin was given for 13-60 days, Voriconazole for up to 100 days. Surgical debridement was performed in all cases and in two cases the created thoracostoma was closed during a second surgical procedure. Aspergillus PCR using blood samples, bronchoalveolar lavage or aspiration fluid was used for monitoring. All four patients had complete clinical and microbiological remission. Our case series shows promising results and underscores the importance of a combined therapeutic approach for Aspergillus pleural empyema consisting of anti-fungal treatment and surgery. Voriconazole and caspofungin seem to be a suitable combination for this infection.
Collapse
Affiliation(s)
- H Bonatti
- Department of General and Transplant Surgery, Innsbruck Medical University, Innsbruck, Austria.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Doyle SC. Aspergillosis prophylaxis and treatment for pediatric HSCT patients: environmental and pharmacologic options. J Pediatr Oncol Nurs 2008; 25:240-6. [PMID: 18660459 DOI: 10.1177/1043454208321118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of viral, bacterial, fungal, and parasitic infections both pretransplant and post-transplant. One of the most dangerous infections that can be acquired during this time is aspergillosis. Several drugs are available for prophylaxis, though no particular regimen has been proven to be superior; although the CDC has clear recommendations regarding prophylaxis for many other infections (such as cytomegalovirus, herpes simplex, toxoplasmosis, and Candida) for HSCT patients, there are none for aspergillosis. Researchers have varying opinions as to which drugs are best for prophylaxis. In this article, pharmacologic and environmental options for prophylaxis are discussed as well as antifungals currently in use, and recommendations on how nurses can help keep their patients safe from this infection are given.
Collapse
Affiliation(s)
- Samatra C Doyle
- Seattle Cancer Care Alliance unit, Children's Hospital and Regional Medical Center, 4500 Sand Point Way NE, Seattle, WA 98105, USA.
| |
Collapse
|
12
|
Tragiannidis A, Papageorgiou T, Theodoridou A, Athanassiadou F, Vyzantiadis T, Kalogera A. Successful treatment of invasive candidiasis with caspofungin in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 49:366-7. [PMID: 16921516 DOI: 10.1002/pbc.21036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
13
|
Collaco JM, Gower WA, Mogayzel PJ. Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: overview, diagnostic considerations, and infectious complications. Pediatr Blood Cancer 2007; 49:117-26. [PMID: 17029246 DOI: 10.1002/pbc.21061] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Pulmonary complications are among the most common and serious sequelae seen in hematopoietic stem cell transplantation (HSCT) recipients. This two-part review addresses the incidence and impact of pulmonary complications in pediatric HSCT patients. In this first part we review the available data for the use of diagnostic modalities in this population, including flexible bronchoscopy with bronchoalveolar lavage (BAL) and open lung biopsy (OLB). We also review the many infectious pulmonary complications that may occur in pediatric HSCT recipients, utilizing the traditional chronologic divisions of neutropenic phase (0-30 days following HSCT), early phase (30-100 days), and late phase (>100 days).
Collapse
MESH Headings
- Anti-Infective Agents/therapeutic use
- Antineoplastic Agents/adverse effects
- Biopsy
- Bronchoalveolar Lavage Fluid
- Bronchoscopy
- Child
- Child, Preschool
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunocompromised Host
- Incidence
- Infant
- Lung Diseases/diagnosis
- Lung Diseases/etiology
- Lung Diseases, Fungal/diagnosis
- Lung Diseases, Fungal/drug therapy
- Lung Diseases, Fungal/epidemiology
- Lung Diseases, Fungal/etiology
- Lung Diseases, Fungal/microbiology
- Neoplasms/complications
- Neoplasms/surgery
- Neutropenia/etiology
- Pneumonia/diagnosis
- Pneumonia/drug therapy
- Pneumonia/epidemiology
- Pneumonia/etiology
- Pneumonia, Bacterial/diagnosis
- Pneumonia, Bacterial/drug therapy
- Pneumonia, Bacterial/epidemiology
- Pneumonia, Bacterial/etiology
- Pneumonia, Bacterial/microbiology
- Pneumonia, Viral/diagnosis
- Pneumonia, Viral/drug therapy
- Pneumonia, Viral/epidemiology
- Pneumonia, Viral/etiology
- Pneumonia, Viral/virology
- Postoperative Complications/diagnosis
- Postoperative Complications/drug therapy
- Postoperative Complications/epidemiology
- Postoperative Complications/etiology
- Postoperative Period
- Time Factors
- Tomography, X-Ray Computed
- Transplantation Conditioning/adverse effects
Collapse
Affiliation(s)
- J Michael Collaco
- Eudowood Division of Pediatric Respiratory Sciences, The Johns Hopkins Medical Institutions, Baltimore, Maryland
| | | | | |
Collapse
|
14
|
Winkler J, Müller U, Nenoff P, Seyfarth HJ, Vogtmann M, Borte G, Pönisch W, Kahn T, Wirtz H, Schauer J, Hoheisel G. Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation. Respiration 2007; 74:663-73. [PMID: 17622755 DOI: 10.1159/000105385] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2006] [Accepted: 02/15/2007] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Invasive pulmonary aspergillosis (IPA) remains a life-threatening condition despite systemic antifungal therapy. OBJECTIVES This retrospective analysis investigated whether additional bronchoscopic instillation of amphotericin B (amB) would improve efficacy of antifungal treatment in patients with haematological malignancies suffering from IPA. METHODS Twenty patients (40.6 +/- 14.2 years, 14 male) with preceding chemotherapy, bone marrow or stem cell transplantation complicated by severe IPA who did not respond sufficiently to systemic antifungal therapy were additionally treated by repeated bronchoscopic instillations of amB solution (91 instillations, on average 4.6 +/- 2.2 instillations per patient over a period of 24.1 +/- 21.0 days). Therapeutic response to this combined treatment regimen was monitored by chest X-ray and CT scan. RESULTS The mean infiltration sizes during systemic antifungal therapy alone (mean duration 11.9 +/- 9.9 days) did not change significantly. However, after additional bronchoscopic instillation of amB solution infiltration sizes were reduced significantly (p < 0.05). A total resolution of infiltrates was seen in 3 and a partial reduction in 13 of 20 patients. Mean duration of total antifungal treatment was 50.1 +/- 24.0 days. The mean follow-up period was 34.1 +/- 31.2 months. The IPA-related mortality rate was 18.8% (3 of 16 patients). CONCLUSIONS Additional bronchoscopic instillation of amB may improve the efficacy of systemic antifungal therapy in patients with haematological malignancies complicated by severe IPA. Bronchoscopic instillation of amB should be considered as an additional treatment option in cases with IPA unresponsive to systemic therapy.
Collapse
Affiliation(s)
- J Winkler
- Pulmonary Unit, Department of Internal Medicine, University of Leipzig, Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Rieder J, Lechner M, Lass-Floerl C, Rieger M, Lorenz I, Piza H, Bonatti H. Successful management of Aspergillus liver abscess in a patient with necrotizing fasciitis. Dig Dis Sci 2007; 52:1548-53. [PMID: 17464562 DOI: 10.1007/s10620-006-9402-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2006] [Accepted: 04/20/2006] [Indexed: 12/09/2022]
Affiliation(s)
- Josef Rieder
- Department of Anaesthesiology and Critical Care Medicine, Medical University, Innsbruck, Austria
| | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
Dunyach C, Eiden C, Jalabert A, Margueritte G, Bernard F, Reynes J, Hansel S. Prise en charge thérapeutique des infections fongiques invasives dans le service d’onco-hématologie pédiatrique du CHU de Montpellier. J Mycol Med 2007. [DOI: 10.1016/j.mycmed.2006.12.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Torrelo A, Hernández-Martín A, Scaglione C, Madero L, Colmenero I, Zambrano A. Primary Cutaneous Aspergillosis in a Leukemic Child. ACTAS DERMO-SIFILIOGRAFICAS 2007. [DOI: 10.1016/s1578-2190(07)70443-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
19
|
López-Ciudad V, Castro-Orjales MJ, León C, Sanz-Rodríguez C, de la Torre-Fernández MJ, de Juan-Romero MAP, Collell-Llach MD, Díaz-López MD. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006; 6:73. [PMID: 16608509 PMCID: PMC1458348 DOI: 10.1186/1471-2334-6-73] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2005] [Accepted: 04/11/2006] [Indexed: 11/23/2022] Open
Abstract
Background Fungal mural endocarditis is a rare entity in which the antemortem diagnosis is seldom made. Seven cases of mural endocarditis caused by Candida spp. have been collected from literature and six of these patients died after treatment with amphotericin B. Case presentation We report a case of mural endocarditis diagnosed by transesophageal echocardiogram and positive blood cultures to Candida parapsilosis. Because blood cultures continued to yield C. parapsilosis despite caspofungin monotherapy, treatment with voriconazole was added. Conclusion This is the first description of successful treatment of C. parapsilosis mural endocarditis with caspofungin and voriconazole.
Collapse
Affiliation(s)
- Víctor López-Ciudad
- Intensive Care Unit, Hospital Santa María Madre-Complejo Hospitalario de Ourense, Ourense, Spain
| | - María J Castro-Orjales
- Intensive Care Unit, Hospital Santa María Madre-Complejo Hospitalario de Ourense, Ourense, Spain
| | - Cristóbal León
- Intensive Care Unit and Emergency Service, Hospital Universitario de Valme, Sevilla, Spain
| | - César Sanz-Rodríguez
- Department of Clinical Research, Merck Sharp & Dohme de España, S.A. Madrid, Spain
| | | | | | - María D Collell-Llach
- Department of Cardiology, Hospital Santa María Madre-Complejo Hospitalario de Ourense, Ourense, Spain
| | - María D Díaz-López
- Unit of Infectious Diseases, Hospital Santa María Madre-Complejo Hospitalario de Ourense, Ourense, Spain
| |
Collapse
|
20
|
Athanassiadou F, Kourti M, Tragiannidis A, Papageorgiou T, Haritanti A, Kaloutsi V, Velegraki A. Pulmonary embolism due to invasive aspergillosis in a child with acute myelogenous leukemia. Pediatr Blood Cancer 2005; 45:1001-2. [PMID: 16047373 DOI: 10.1002/pbc.20517] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|